Frontotemporal dementia (FTD) encompasses a spectrum of neurodegenerative diseases with varied biological mechanisms, clinical symptoms and prognoses that come with unique challenges for clinical drug development. There are currently no approved treatments that delay or halt the progression of FTD disorders or that effectively treat symptoms. While there are increasing numbers of promising treatments entering clinical trials, the number remains small, and none have resulted in viable treatments.
The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) launched the Treat FTD Fund to provide critical funding for early-stage clinical trials that:
- help address these challenges
- build on emerging scientific understanding of biological mechanisms underlying FTD
- stimulate the field to develop new therapies for FTD disorders
- advance the development, validation and adoption of informative biomarkers
- enable novel trial designs and technologies
Deadlines for Letters of Intent: Jan. 27, 2023
Funding is open to researchers and clinicians worldwide at:
- Academic medical centers, universities or non-profits. Industry partnerships are encouraged.
- Biotechnology companies. Existing companies and new startups are both eligible.
- NOTE: All funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).
Up to $2,000,000 based on stage and scope of the trial. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and patient enrollment.